Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com
Insulet Corporation's stock has reached a new 52-week low of $199.53, despite strong fundamentals like a $14.3 billion market cap and 31% revenue growth over the past year. InvestingPro data suggests the stock is oversold with upward revisions from analysts, indicating it may be undervalued. The company recently reported strong Q4 sales but faces increased competition and has initiated a voluntary recall for some Omnipod 5 Pods due to a manufacturing issue.
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer
Insulet Corporation (NASDAQ:PODD) has appointed Mike Panos as its Executive Vice President and Chief Commercial Officer, effective immediately. Panos brings 30 years of medical technology commercial leadership experience and will lead the company's global commercial organization. The announcement comes as Insulet faces increasing competition and recently addressed a voluntary device correction for certain Omnipod 5 lots, which Truist believes will have a manageable impact.
Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com
Insulet Corporation's stock reached a new 52-week low of $199.53, despite strong fundamentals, recent impressive quarterly sales, and analysts revising earnings upwards. The company saw robust revenue growth and its stock is considered undervalued and oversold by InvestingPro. However, growing competition and a recent product recall have led several analysts to lower their price targets.
Insulet Corporation stock hits 52-week low at 199.53 USD
Insulet Corporation's stock has hit a new 52-week low of $199.53, despite the company's strong fundamentals including a $14.3 billion market cap and 31% revenue growth. InvestingPro data suggests the stock is oversold and undervalued, with analysts revising earnings upwards. The decline comes amidst growing competition, recent price target cuts by analysts, a voluntary product recall, and a new executive appointment.
Insulet (NASDAQ:PODD) Cut to Neutral at Citigroup
Citigroup downgraded Insulet (NASDAQ:PODD) from a "buy" to a "neutral" rating and reduced its price target to $230 from $338, indicating a potential 13% upside. This adjustment comes despite Insulet beating Q1 earnings estimates with $1.55 EPS and $783.8 million in revenue, a 31.2% year-over-year increase. The consensus among analysts remains a "Moderate Buy" with an average target of $349.10.
Smart Insulin Management Devices Market is expected to Hit US$ 27.07 Billion by 2033 | Major Companies - Abbott, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company
The Smart Insulin Management Devices Market reached US$ 12.93 Billion in 2024 and is projected to grow to US$ 27.07 Billion by 2033, exhibiting an 8.6% CAGR during the forecast period. This growth is driven by advanced medical devices integrating insulin delivery with real-time monitoring and data analytics to optimize diabetes care. Key players include Abbott, Medtronic, and Eli Lilly, with significant industry developments in cloud-based AI analytics, bundled reimbursement programs, and closed-loop automated insulin delivery systems.
Citi Downgrades Insulet Corporation (PODD) to Neutral
Citi analyst Joanna Wuensch downgraded Insulet Corporation (NASDAQ: PODD) to Neutral. The article is premium-only content, requiring a subscription to StreetInsider.com to view the full details of the downgrade.
Diabetes device recall surge reveals a worrying information gap
The article highlights a significant increase in diabetes device recalls, particularly for continuous glucose monitors (CGM) and insulin pumps, indicating a growing problem in the medical device industry. This surge in recalls suggests a concerning information gap related to the safety and efficacy of these essential medical devices. The report mentions specific Class I and Class II recalls in 2025 involving major companies like Abbott Laboratories, Tandem Diabetes Care, Dexcom, Medtronic, and Insulet Corp.
Robust 2025 growth, new leadership in Insulet (NASDAQ: PODD) 2026 proxy
Insulet's 2026 proxy statement highlights strong financial performance in 2025, with revenue reaching approximately $2.7 billion and robust growth in its Omnipod business. The company emphasizes its shareholder-aligned executive compensation and governance practices, alongside sustainability initiatives. Shareholders are asked to vote on the election of three Class I directors, executive compensation, and the ratification of the independent auditor at the upcoming virtual annual meeting.
Insulet announces recall of Omnipod 5 Pods due to insulin delivery issue
Insulet Corporation is recalling specific lots of its Omnipod 5 Pods in the United States due to a manufacturing defect that could cause insulin to leak inside the Pod instead of being delivered to the user. This issue may lead to under-delivery of insulin, causing high blood glucose levels, and has been linked to 18 serious adverse events including hospitalizations and diabetic ketoacidosis. Users are advised to check their Pod lot numbers at omnipod.com/check-pods and discontinue use of affected Pods and request free replacements, while Insulet maintains ongoing supply.
Insulet announces recall of Omnipod 5 Pods due to insulin delivery issue
Insulet Corporation has issued a recall for specific lots of its Omnipod 5 Pods in the U.S. due to a manufacturing defect that can cause insulin to leak internally, leading to under-delivery to users. The company has reported 18 serious adverse events, including hospitalizations and diabetic ketoacidosis, but no fatalities. Consumers are advised to check their Pod lot numbers online and replace any affected Pods, with Insulet ensuring continued production and availability.
Assessing Insulet (PODD) Valuation After Omnipod 5 Device Correction And Maintained Outlook
Insulet (PODD) recently underwent a voluntary device correction for its Omnipod 5, following 18 adverse events, yet it has maintained its financial outlook. Despite this and recent executive changes, the company's shares show fading momentum over the past year. Analysts are split on the valuation, with some models suggesting significant undervaluation while others point to a high P/E ratio, making it crucial for investors to assess the company's long-term growth prospects against current market pricing.
Insulet Corp (PODD) EVP receives new stock options and RSU awards
Insulet Corp's EVP and CCO, Michael Panos, was granted new equity awards including 7,255 employee stock options with an exercise price of $207.04 and 2,777 restricted stock units (RSUs) on April 1, 2026. These awards vest over several years, with options vesting over four years and RSUs over three years, both designed to align his incentives with the company's long-term performance. Following these grants, Panos directly holds 2,782 common shares and 7,255 stock options.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell shares are falling, what you need to know
This article indicates that shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell are currently experiencing a decline. The title suggests that the content would provide an explanation for these drops, but the article text itself is not provided.
INSULET CORP (PODD) EVP and CCO Michael Panos reports 5-share stake
Michael Panos, EVP and Chief Commercial Officer of INSULET CORP (PODD), has filed an initial Form 3, disclosing direct beneficial ownership of 5 shares of the company's common stock. This filing establishes his starting equity position as an insider, and it does not represent a recent buy or sell transaction.
Insulet (PODD) board member elects 111 deferred stock units as fees
Insulet director Robert Luther Huffines received 111 deferred common stock units valued at $209.84 per unit on March 31, 2026, as compensation instead of cash board fees. This grant increased his holdings to 638 shares or units. The units will convert to Insulet common shares upon distribution, which can be a lump sum or in annual installments, as per the company's Deferred Compensation Plan for Non-Employee Directors.
Insulet Corp. stock outperforms competitors despite losses on the day
Insulet Corp. (PODD) shares dropped 1.32% to $204.31 on Thursday, marking its second consecutive day of losses. Despite this, the stock still outperformed the broader market, as the S&P 500 Index rose slightly and the Dow Jones Industrial Average experienced a small decline on the same day.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD
Pomerantz LLP is investigating potential claims against Insulet Corporation (NASDAQ: PODD) on behalf of investors. This follows a significant drop in Insulet's stock price after the company announced a voluntary Medical Device Correction for certain Omnipod 5 Pods due to a manufacturing issue. Investors affected by this decline are encouraged to contact the law firm to learn about potential class action participation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insulet Corporation (PODD) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Insulet Corporation (NASDAQ:PODD) shareholders following a significant stock price drop. The investigation comes after Insulet disclosed a voluntary Medical Device Correction for specific Omnipod® 5 Pod lots due to a manufacturing issue. Shareholders who purchased Insulet securities are encouraged to contact the firm to assist with the investigation.
Intuitive Surgical Stock Near Crucial Support – Buy Signal?
Intuitive Surgical (ISRG) stock is currently trading within a crucial support zone, having bounced significantly from these levels multiple times in the past. The article suggests a rebound is likely due to robust sector growth, strong Q4 2025 performance, and a growing robotic surgery market. Despite competitive pressures and an elevated valuation, analyst targets imply significant upside, while technical indicators like an oversold RSI also support a potential bounce.
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation announced it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, before market open. Management will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results. Details for accessing the live webcast and replay will be available on the company's investor relations website.
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
William Blair initiated coverage on MiniMed Group Inc. (NASDAQ: MMED), highlighting its recovery story despite past competitive setbacks. The company, a unit of Medtronic Plc, is improving its product pipeline with new innovations like the MiniMed Flex, a next-generation insulin pump cleared by the FDA. Despite facing ongoing competition and profitability challenges, its valuation presents an attractive risk-reward profile for investors.
Medtronic plc Stock: Navigating Transformation and Growth in MedTech Amid Analyst Shifts
Medtronic plc is undergoing a significant transformation, including a planned spinoff of its MiniMed diabetes business, and reported strong Q3 FY2026 results with revenue of $9.02 billion. The company is focused on high-margin therapies and boasts a robust dividend policy, approaching Dividend King status. While analysts show mixed views, with Barclays raising its target to $120, execution risks related to the spinoff and competitive pressures remain key areas for investors to monitor.
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation (NASDAQ: PODD) announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026, before the financial markets open. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results, with access details available on its investor relations website. Insulet is a global leader in tubeless insulin pump technology through its Omnipod® brand, simplifying diabetes management.
Insulet Corp. stock underperforms Wednesday when compared to competitors
Insulet Corp. (PODD) stock fell 1.33% to $207.04 on Wednesday, underperforming the broader market despite gains in the S&P 500 and Dow Jones Industrial Average. The company's shares closed 41.66% below their 52-week high of $354.88, reached on November 20th. This performance occurred on an otherwise favorable trading day for the stock market.
Insulet Corporation Trade Ideas — MIL:1PODD
This article compiles various trade ideas and technical/fundamental analyses for Insulet Corporation (1PODD, NASDAQ:PODD). Analysts offer diverse perspectives, including long positions based on strong earnings, technical breakouts like "cup with handle" formations, and potential gap fills, alongside a bearish signal. The company's fundamentals, such as high EPS and sales growth, and a significant insider buy are highlighted.
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a potential securities fraud lawsuit against Insulet Corp. (NASDAQ: PODD). This follows a voluntary medical device correction disclosing a design defect in Omnipod 5 insulin pods that led to insulin leakage and serious adverse events. The firm is investigating whether the company concealed this defect from investors before its public disclosure.
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky
Levi & Korsinsky is investigating a potential securities fraud lawsuit against Insulet Corp. after the company disclosed a voluntary medical device correction for its Omnipod 5 insulin pods due to a design defect causing insulin leakage, which led to eighteen serious adverse events. Insulet's shares fell by approximately 6.9% following the 8-K filing on March 12, 2026. The lawsuit will examine whether executives concealed the defect, especially given CEO Ashley McEvoy's positive statements about Omnipod's reliability during the Q4 2025 earnings call on February 18, 2026, which preceded the disclosure of the serious adverse events.
Insulet Corp. Stock Hits 52-Week Low at USD 208.14
Insulet Corp. (a small-cap pharmaceutical and biotechnology company) recently reached a new 52-week low of USD 208.14 on March 27, 2026, significantly underperforming the S&P 500 over the past year. Despite healthy long-term growth in sales and operating profit, the company faces challenges with a high price-to-earnings ratio, low return on capital employed, and a decline in net profit. These financial dynamics are leading to increased market scrutiny.
Inogen appoints Jason Richardson as CFO to support growth
Inogen, Inc. has announced several leadership appointments, including Jason Richardson as the new Chief Financial Officer, effective April 6, 2026. Richardson, who previously held senior finance roles at Baxter International Inc., succeeds Michael Bourque. The company also appointed Dominic Hulton as Chief Marketing Officer and Corey Moritz as Vice President, U.S. Business to Business Sales, with these changes aimed at accelerating Inogen's growth and strengthening its market presence.
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026, before the financial markets open. Following the release, the company will host a conference call at 8:00 a.m. (Eastern Time) to discuss the results. The call details and webcast link will be available on Insulet's Investor Relations website.
Segmentation, Major Trends, and Competitive Dynamics in the Insulin Patch Pumps Market
The global insulin patch pumps market is projected to reach $2.55 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in diabetes care technology and increased adoption of closed-loop systems. Key players like Insulet Corporation and Medtronic PLC are innovating with products like the Embecta insulin patch pump, which recently received FDA clearance. The market is segmented by type (reusable, disposable, smart, automated), mode (basal, bolus), and application (Type 1 and Type 2 diabetes), reflecting diverse patient needs and technological progress.
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation (NASDAQ: PODD) announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026, before the financial markets open. Management will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results. Insulet is a medical device company specializing in tubeless insulin pump technology through its Omnipod® brand.
7,473 Shares in Insulet Corporation $PODD Acquired by J. Safra Sarasin Holding AG
J. Safra Sarasin Holding AG recently acquired 7,473 shares of Insulet Corporation ($PODD) stock, valued at approximately $2.124 million, during the fourth quarter. This highlights institutional interest, further supported by insider buying from director Michael R. Minogue, who increased his holdings by 13.14% in February. Insulet also exceeded Q1 earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $354.24.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ...
Pomerantz LLP is investigating potential securities fraud claims against Insulet Corporation on behalf of its investors. This investigation follows Insulet's disclosure of a voluntary Medical Device Correction for specific lots of its Omnipod® 5 Pods due to a manufacturing issue. After this news, Insulet's stock price dropped significantly, leading to the law firm's inquiry into possible unlawful business practices by the company's officers and/or directors.
Why (PODD) Price Action Is Critical for Tactical Trading
This article analyzes Insulet Corporation (NASDAQ: PODD) using AI models, identifying weak sentiment across all horizons and suggesting a short bias. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for tactical trading decisions. The report emphasizes elevated downside risk due to a lack of additional long-term support signals.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ...
Pomerantz LLP is investigating Insulet Corporation (NASDAQ: PODD) on behalf of its investors, following a significant drop in stock price. This investigation comes after Insulet announced a voluntary Medical Device Correction for certain lots of its Omnipod® 5 Pods due to a manufacturing issue. The news led to Insulet's stock price falling by $16.92 per share, or 6.88%, on March 13, 2026.
Insulet hires Stryker vet, reinstating commercial chief role as C-suite overhaul continues
Insulet has reinstated the chief commercial officer position, hiring Mike Panos, a veteran from Stryker, to fill the role. This move comes as part of a broader C-suite reorganization under CEO Ashley McEvoy, aiming to capitalize on significant growth opportunities in automated insulin delivery. Panos will oversee an expanded sales force, with other leadership changes including Eric Benjamin as COO and Manoj Raghunandanan as chief growth officer.
Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD
Zevenbergen Capital Investments LLC has acquired a new stake of 113,083 shares in Insulet Corporation (NASDAQ:PODD), valued at approximately $32.14 million. This investment makes Zevenbergen Capital Investments LLC the owner of about 0.16% of Insulet. Other significant institutional investments were also made by Norges Bank, Qube Research & Technologies Ltd, and Worldquant Millennium Advisors LLC, while Squarepoint Ops LLC and Munro Partners substantially increased their holdings.
Inogen makes three appointments to exec team
Inogen has appointed three new members to its executive team to accelerate its next phase of growth. Jason Richardson will serve as CFO, Dominic Hulton as chief marketing officer, and Corey Moritz as vice president, U.S. business-to-business sales. These strategic hires bring extensive experience in finance, marketing, and commercial transformation from the medical device and healthcare industries.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Insulet Corporation (NASDAQ:PODD) following a significant drop in its stock price after the company disclosed a voluntary Medical Device Correction for specific lots of its Omnipod® 5 Pods due to a manufacturing issue. The firm is encouraging shareholders who purchased Insulet securities to learn more about the investigation to potentially recover losses. This investigation seeks to determine if there are grounds for a class action on behalf of affected investors stemming from the alleged manufacturing issue and subsequent stock decline.
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement
Truist has reiterated its Buy rating on Insulet Corporation (PODD) following the company's announcement of a global field safety correction for its Omnipod 5 Automated Insulin Delivery System. The correction addresses a software issue that could lead to over-delivery of insulin, but Truist believes the impact on Insulet's financials, new patient starts, and market share loss will be minimal given the low historical incidence rate of the flaw and the company's proactive communication.
Insulet Earnings: Stellar Finish to 2025 With Strong Fourth Quarter
Insulet reported strong fourth-quarter 2025 results, with revenue growing 29% in constant currency, largely driven by 42% growth internationally. The company also saw an expansion in its quarterly operating margin by 40 basis points, leading to an approximately 8% rise in its shares during early trading. This performance indicates a robust conclusion to 2025 for Insulet.
Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy?
Insulet Corporation recently appointed Mike Panos as Executive Vice President and Chief Commercial Officer, signaling a potential shift towards disciplined commercial execution and talent development. Panos's extensive experience at Stryker suggests a focus on broadening Insulet's global reach and patient populations. This hire comes as Insulet navigates a Medical Device Correction for its Omnipod 5 platform, highlighting the crucial role of commercial leadership in maintaining market trust and growth.
Consumer safety roundup: Major recalls affect Einstein Bros., Insulet, Amneal and Falcon Trading
This article details several major product recalls announced by the FDA, affecting multiple companies due to various safety hazards. Einstein Bros. Bagels recalled mislabeled honey cream cheese containing almonds, Insulet Corporation recalled Omnipod Insulin Management Systems due to a manufacturing defect, Amneal Pharmaceuticals recalled mispackaged magnesium sulfate IV bags, and Falcon Trading Company recalled organic bean and soup mixes due to pesticide contamination. Consumers are advised to take immediate action, including discarding products or seeking replacements, to mitigate potential health risks.
Insulet Corp (PODD) Shares Down 4.53% on Mar 30
Shares of Insulet Corp (PODD) fell 4.53% on March 30, reaching an intraday low of $208.14. Despite the drop, analysts project an average target price of $356.57, suggesting a 71.24% upside. GuruFocus also estimates a fair value of $466.93, indicating a potential upside of 124.25%.
Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy?
Insulet Corporation has appointed Mike Panos, a seasoned medical technology commercial leader from Stryker, as their new Executive Vice President and Chief Commercial Officer. This hire suggests Insulet is emphasizing disciplined commercial execution and talent development to expand its global reach with the Omnipod platform. Panos's expertise will be crucial in navigating challenges like the recent Omnipod 5 Medical Device Correction and maintaining growth against competition.
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Inogen, Inc. has announced several key leadership appointments to accelerate its next phase of growth. Jason Richardson has been named Chief Financial Officer, succeeding Michael Bourque. Dominic Hulton has been appointed Chief Marketing Officer, and Corey Moritz has joined as Vice President, U.S. Business to Business Sales. The company also reaffirmed its financial outlook for the first quarter and full year 2026.
Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026
Insulet Corporation has announced the appointment of Mike Panos as Executive Vice President and Chief Commercial Officer, effective March 30, 2026. Panos will lead the global commercial organization, reporting to President and CEO Ashley McEvoy, and brings 30 years of medical technology commercial leadership experience from Stryker Corporation. His role will involve driving commercial strategy, expanding market access, and strengthening capabilities for continued growth.
Insulet names Mike Panos as chief commercial officer
Insulet Corporation has appointed Mike Panos as its Executive Vice President and Chief Commercial Officer, effective immediately. Panos brings 30 years of commercial leadership experience from the medical technology sector, most recently from Stryker Corporation. This appointment comes as Insulet's stock trades near its 52-week low, despite strong revenue growth and a high gross profit margin.
